Document Detail


Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study.
MedLine Citation:
PMID:  23043261     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Studies of the carcinogenic potential of benzodiazepines and related drugs (BZRD) have been equivocal. A recent study reported a 35% excess cancer risk among users of hypnotics, including benzodiazepines. METHOD: Using Danish nationwide registers, we conducted a matched case-control study of the association between BZRD and cancer risk. During 1.1.2002-31.12.2009, we identified 152,510 cases with a first time cancer who were matched (1:8) by age and gender to 1,220,317 cancer-free controls. A new-user design was applied by excluding all subjects who had used anxiolytics, hypnotics or sedatives during the first two years of available prescription data (1995-6). Odds ratios (ORs) with 95% confidence intervals (CI) were estimated using conditional logistic regression, adjusting for potential confounders. In the primary analysis, long-term use of BZRD was defined by a cumulative amount of ≥500 defined daily doses of BZRD within a period of one to five years prior to the index date. RESULTS: The adjusted OR for cancer associated with BZRD use was 1.09 (CI, 1.04-1.14). ORs were close to unity for most cancer sites, except stomach 1.40 (1.05-1.88), oesophagus 1.43 (1.01-2.02), liver 1.81 (1.18-2.80), lung 1.38 (1.23-1.54), pancreas 1.35 (1.02-1.79), and kidney 1.39 (1.01-1.91). For tobacco-related cancers, the OR was 1.15 (1.09-1.22), and for the remaining cancer sites 1.01 (0.94-1.08). Sub-group analyses revealed only small differences between different levels of exposure or different patient subgroups. CONCLUSION: BZRD use was not associated with an overall increase in cancer risk, except for what is likely explained by minor life-style confounding, e.g., smoking.
Authors:
Anton Pottegård; Søren Friis; Morten Andersen; Jesper Hallas
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-9
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  -     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Affiliation:
Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Winsløwparken 19, DK-5000, Odense C.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Frnakenstein: multiple target inverse RNA folding.
Next Document:  Combining QOF data with the care bundle approach may provide a more meaningful measure of quality in...